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CD8 T cells are a crucial component of the 
adaptive  immune  response  to  malignancies. 
Antigen-experienced CD8 T cells specific for 
tumor  antigens  can  be  recovered  from  the 
blood, lymphoid organs, and tumors of both 
cancer  patients  and  tumor-bearing  mice.  In 
multiple mouse tumor models, CD8 T cells are 
required for the immune control or rejection 
of the tumor (Dunn et al., 2004). In addition, 
recent studies have shown that the presence of 
tumor-infiltrating lymphocytes (TIL) is a posi-
tive prognostic factor for patients with colorec-
tal, ovarian, esophageal, and pancreatic cancer, 
as well as for melanoma and glioma patients 
(Galon et al., 2006; Pagès et al., 2010). Multiple 
groups, including our own, have shown robust 
activation of CD8 T cells in the tumor-draining 
LNs  over  the  course  of  tumor  outgrowth 
(Marzo et al., 1999; Bai et al., 2001; Wolkers   
et al., 2001; Spiotto et al., 2002; Hargadon   
et al., 2006). Although two previous studies at-
tempted to address the tumor as a potential site 
of naive T cell activation, they relied on temporal 
separation of the appearance of activated T cells 
in the draining LN and tumor (Bai et al., 2001) 
or used tumors at an early stage of growth 
(Shrikant and Mescher, 1999) that may not ac-
curately reflect the structure, environment, and 
activating  potential  of  an  established  tumor 
(Schreiber et al., 2006). Thus, the potential for 
the tumor to serve as a site of naive T cell acti-
vation remains largely unexplored.
The  tumor  mass  is  an  attractive  site  of   
T cell priming, as it provides a large depot of 
antigen and contains multiple cell types that could 
present  that  antigen  (Balkwill  and  Mantovani, 
2001). Cross-presentation of tumor antigen by 
DCs in the tumor-draining LN (Nelson et al., 
2001;  Wolkers  et  al.,  2001;  Nguyen  et  al., 
2002; Spiotto et al., 2002; Nowak et al., 2003; 
Hargadon et al., 2006), as well as direct presenta-
tion by tumor cells that have migrated to the 
tumor-draining  LN  (Wolkers  et  al.,  2001;   
Hargadon et al., 2006), have been demonstrated. 
In addition, BM-derived stromal cells within 
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Studies of T cell responses to tumors have focused on the draining lymph node (LN) as the 
site of activation. We examined the tumor mass as a potential site of activation after 
adoptive transfer of naive tumor-specific CD8 T cells. Activated CD8 T cells were present in 
tumors within 24 h of adoptive transfer and proliferation of these cells was also evident  
4–5 d later in mice treated with FTY720 to prevent infiltration of cells activated in LNs.  
To confirm that activation of these T cells occurred in the tumor and not the tumor-draining 
LNs, we used mice lacking LNs. Activated and proliferating tumor-infiltrating lymphocytes 
were evident in these mice 24 h and 4 d after naive cell transfer. T cells activated within 
tumors acquired effector function that was evident both ex vivo and in vivo. Both  
cross-presenting antigen presenting cells within the tumor and tumor cells directly  
presenting antigen activated these functional CD8 effectors. We conclude that tumors 
support the infiltration, activation, and effector differentiation of naive CD8 T cells,  
despite the presence of immunosuppressive mechanisms. Thus, targeting of T cell activation 
to tumors may present a tool in the development of cancer immunotherapy.
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T cells. Lung, s.c., or i.p. B16-F1 or B16-cOVA tumors were 
established in C57BL/6 mice. Naive OT-I T cells were then 
transferred into these mice and LN, spleen, and tumor were 
evaluated 24 h later. Naive OT-I cells were present in B16-F1 
tumors growing in all locations, indicating that they could in-
filtrate tumors in the absence of antigen. (Fig. 1 A). Host- 
derived CD8 T cells with a naive surface phenotype (CD44lo) 
were also present among the TIL (Fig. S1 A), suggesting that 
naive endogenous CD8 T cells also infiltrate tumors. OT-I 
cells were also present in B16-cOVA tumors 24 h after transfer, 
but a majority displayed an activated phenotype based on ex-
pression of CD69 and CD25 (Fig. 1 B). The concurrent pres-
ence of naive and activated OT-I cells in B16-cOVA tumors 
24 h after transfer suggests that activation occurs within the 
tumor when cognate antigen is present.
OT-I cells found in tumors 24 h after transfer were 
activated in situ and are localized within tumor parenchyma
T cells activated 24 h after transfer were found not only in the 
B16-cOVA tumors growing in different locations but also in 
the tumor-draining LN and in the case of lung tumors, the 
the tumor have been shown to present antigen to differenti-
ated effectors (Zhang et al., 2007) and activated CD8 T cells 
have been shown to proliferate further within the microenvi-
ronment of brain tumors (Masson et al., 2007). However, it is 
not known whether intratumoral DCs/myeloid cells or tumor 
cells can activate naive CD8 T cells within the tumor mass.
Naive T cells follow a restricted migratory pattern through 
blood, LN, and efferent lymph because of their high ex-
pression of CD62L and CCR7 and their low expression of   
tissue-specific adhesion molecules and chemokine receptors   
(von Andrian and Mackay, 2000). Therefore, a central ques-
tion is whether naive T cells could access tumor masses in 
nonlymphoid tissues. However, multiple studies have also 
demonstrated that naive T cell infiltrate peripheral tissues as 
part of their normal migratory activity (Westermann et al., 
1996; Zippelius et al., 2004; Cose et al., 2006; Galkina et al., 
2006; Staton et al., 2006). Most recently, T cells with a naive 
phenotype have been detected in skin, lung, liver, lamina 
propria, and brain (Cose et al., 2006). Although tumors manipu-
lated to express LIGHT (Yu et al., 2004) or lymphotoxin  
(Schrama et al., 2001; Kim et al., 2004) can attract naive   
T cells, the ability of naive T cells to infiltrate unmanipulated 
tumors has not been addressed.
A final consideration is whether the tumor microenvi-
ronment will support or suppress the activation of naive   
T cells. Tumors contain a diverse array of immune cells and 
proinflammatory cytokines (Balkwill and Mantovani, 2001; 
Coussens and Werb, 2002). Tumor invasion into normal tis-
sue, hypoxia, and necrosis can augment this inflammatory   
response. However, tumors are also considered to be immuno-
suppressive. Myeloid-derived suppressor cells, T reg cells, IDO, 
and TGF- have all been associated with the presence of 
dysfunctional CD4 and CD8 TILs (Zou, 2005; Rabinovich 
et al., 2007). If naive T cells access the antigen presentation 
within tumors, the presence of immunosuppression might limit 
their potential for activation and differentiation.
In this study, we directly address whether naive T cells 
can infiltrate normal tumors and become activated there. We 
separated T cell activation in the tumor-draining LN from 
that potentially occurring in the tumor mass using FTY720, 
a drug that prevents the egress of T cells from LNs, and using 
mice lacking LNs. These methods also allowed us to track the 
outcomes of T cell activation in each location and examine 
the effector differentiation and functional activity of T cells 
activated within tumors. Our work demonstrates that naive 
CD8 T cells can infiltrate tumors, become activated there, 
and differentiate into functional effectors.
RESULTS
Naive and activated T cells are found in B16 melanoma 
tumors 24 h after transfer
To explore the potential for naive T cells to infiltrate tumors 
and become activated there, we used B16-F1 melanoma cells 
stably transfected with cytoplasmically expressed chicken OVA 
(B16-cOVA). These cells present the OVA257 epitope in the con-
text of H2-Kb, which is recognized by OT-I TCR transgenic 
Figure 1.  Naive and activated OT-I cells are found within B16 
melanoma tumors 24 h after transfer into mice. C57BL/6 mice bear-
ing established s.c. (17–21-d-old), lung (17–21-d-old), or i.p. (10–15-d-old) 
B16-F1 (A) or B16-cOVA (B) tumors received Thy1-mismatched OT-I  
T cells. Axes on plots are displayed in Logicle scale. 24 h later, lymphocytes 
from tumors, LN, and spleen were harvested and stained for flow  
cytometry. Plots are gated on Thy1.1+ CD8+ lymphocytes, and numbers 
indicate the percentage of OT-I cells that are single positive for CD69 or 
CD25, or positive for both markers. Tumor location is noted to the right of 
dot plots. Results are representative of at least three independent  
experiments, with five or more mice each per tumor location.JEM VOL. 207, August 2, 2010 
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subcutaneous tumors, and injected with OT-I cells when the   
tumors were established. 24 h after T cell transfer, OT-I cells had 
infiltrated the residual mesenteric LN, liver, lung, and BM.   
However, these cells remained uniformly naive (Fig. 2 B).   
In contrast, robustly activated OT-I cells were found in tumors at 
this time. Similar results were observed in animals with established   
lung tumors (Fig. S2). These results demonstrate that naive CD8   
T cells infiltrate established tumors and become activated there.
As it is not technically feasible to flush the tumor vasculature 
of passenger leukocytes, we sought to confirm that OT-I cells 
were actually located within tumors, and not merely in tumor-
associated vasculature. Using immunofluoresence and anti– 
Thy-1.1 antibody, OT-I cells were observed both deep within 
tumor parenchyma and in a perivascular configuration (Fig. 2,   
C and D). Although we expect that some naive OT-I cells do 
remain in the bloodstream, our observations indicate that the 
OT-I cells are located intratumorally, consistent with their   
having encountered antigen in that location.
Characteristics of T cells infiltrating tumors
We hypothesized that some naive OT-I cells might express 
chemokine receptors or adhesion molecules that could enable 
spleen (Fig. 1 B). The absence of activated T cells in nondraining 
LN (Fig. 1 B) at this time suggested that they had not moved 
from their initial site of activation in appreciable numbers. To 
address this possibility more directly, we evaluated whether   
OT-I cells activated in a lymphoid organ accumulate within   
24 h in established B16-F1 tumors, which cannot serve a site of 
their activation. 17–21 d after intravenous injection of B16-F1 
to create lung tumors, mice were injected with B16-cOVA cells 
via the same route to target tumor-draining lymphoid organs 
(Hargadon et al., 2006). Naive OT-I cells were transferred 24 h 
later. Activated OT-I cells were found in lung tumor-draining 
mediastinal LN and spleen, but not in the B16-F1 tumor (Fig. 2 
A). This strongly suggests that activated T cells do not move 
from the draining lymphoid organs within 24 h.
A possible limitation of the above experiment is that specific 
antigens might be required to retain OT-I cells in the tumor. 
To directly demonstrate that OT-I cells could be activated within 
the tumor, we used in utero administration of lymphotoxin– 
receptor–Ig and TNF receptor 55–Ig fusion proteins to block the 
formation of all LNs except for a small residual mesenteric   
LN (Rennert et al., 1998). At 8 wk of age, these mice   
were splenectomized, inoculated with B16-cOVA to form   
Figure 2.  OT-I cells found in tumors 
24 h after transfer were activated in 
situ and are localized within tumor  
parenchyma. (A) C57BL/6 mice bearing  
established B16-F1 lung tumors were  
challenged with B16-cOVA via the lateral 
tail vein, followed 24 h later by Thy1- 
mismatched OT-I cells. Lungs/tumors, LN, 
and spleen were harvested 24 h later, and 
lymphocytes were stained for flow cytom-
etry. Results represent three independent 
experiments. n = 3. (B) C57BL/6 mice lack-
ing LN after in utero ablation were splenec-
tomized and injected s.c. with B16-cOVA 3 wk 
later. After tumors were established, mice 
were injected with Thy1.1+ OT-I cells. Tumors 
and indicated tissues were harvested 24 h 
later, and lymphocytes were stained for 
flow cytometry. Results are an example of  
n = 4 animals in 2 independent experiments. 
All plots in (A and B) are gated on Thy1.1+ 
CD8+ OT-I lymphocytes, and numbers indi-
cate the percentage of OT- I cells that are 
single positive for CD69 or CD25, or posi-
tive for both markers. Axes on plots are 
displayed in Logicle scale. (C and D) Naive 
OT-I T cells were transferred into mice 
C57BL/6 mice bearing established lung  
(C) or s.c. (D) B16-cOVA tumors. Localiza-
tion of OT-I cells within tumors was visual-
ized via their Thy1.1 staining and CD31 
staining on tumor vasculature. Images are 
representative of multiple fields and  
magnifications of three lung and s.c.  
tumors in three independent experiments. 
Bars, 200 µm.1794 Activation of naive T cells in tumor masses | Thompson et al.
tumor as compared with the tumor-draining LN 24 h after 
bulk OT-I transfer (Fig. S3 A). These results indicate that the 
presence of naive and activated T cells within tumors does 
not depend on CD44hi cells in the transferred population.
Small  populations  of  naive  OT-I  cells  also  expressed 
CD11a and/or 4. 24 h after transfer into s.c. B16-cOVA 
tumor-bearing animals, OT-I cells expressing 4 or CD11a 
were highly enriched among cells infiltrating the tumor as 
compared with the draining LN (Fig. S3 A). These two 
molecules  were  only  partially  coexpressed  (unpublished 
data).  In  addition,  4+  and  CD11a+  cells  also  expressed 
higher levels of those molecules as compared with their   
4+ and CD11a+ counterparts in the tumor-draining LN   
(Fig. S3 B). This suggests that naive OT-Is expressing higher 
levels of 4 and/or CD11a preferentially enter the tumor 
over the draining LN.
Endogenous lymphocytes are not required for naive T cell 
infiltration into tumors or their in situ activation
To determine whether endogenous lymphocytes that have 
accumulated in the tumor over the course of its development 
are required to support naive OT-I infiltration or intratumoral 
activation, we evaluated RAG2/ mice. After transfer into 
RAG2/ mice bearing established s.c. B16-cOVA tumors, 
OT-I cells were present in the tumor, and a large fraction dis-
played an activated phenotype in both the tumor and the 
draining LN (Fig. 4). The representation of activated cells in 
the tumor was comparable to that seen in control animals. 
These results demonstrate that endogenous B and T cells are 
not required to support the infiltration of naive OT-I cells 
into B16 tumors or their local activation there. Furthermore, 
these results show that the initiation of the OT-I response can 
occur within the tumor microenvironment, without prior 
endogenous cell recruitment.
them  to  infiltrate  tumors.  Although  the  vast  majority  of 
freshly  isolated  naive  CD8  T  cells  expressed  CD62L  and 
CCR7, 5–10% of the naive OT-I cells transferred in the 
aforementioned experiments were CD44hi (Fig. 3 A). To   
determine whether these “memory-like” cells might be the 
rapid tumor-infiltrating cells, we evaluated the relative infil-
tration  of  unlabeled  bulk  OT-I  cells  and  CFSE-labeled, 
CD44-depleted OT-I cells. 24 h after cotransfer into mice 
bearing s.c. or i.p. B16-cOVA tumors, the ratio of these two 
populations in the tumor was equivalent to the input ratio 
and to that observed in all evaluated lymphoid compartments 
(Fig. 3, B–D). In addition, activation occurred in both   
the bulk and CD44-depleted OT-I populations within the   
tumor. CD44+ OT-I cells were also not enriched in the   
Figure 3.  Naive T cell tumor infiltration and intratumoral  
activation does not require the presence of CD44hi cells. (A) Expres-
sion of CD44 on CD8 cells from pooled LN and spleen of an OT-I Thy1.1+ 
mouse. (B) A 70:30 mixture of CFSE-labeled, CD44-depleted, and unla-
beled bulk OT-I cells was transferred into Thy1-mismatched mice bearing 
established s.c. (C) or i.p. (D) tumors. 24 h after transfer, tumors, LN, and 
spleen were harvested and lymphocytes were stained for flow cytometry. 
Plots are gated on Thy1.1+ CD8+ lymphocytes. Numbers in the top row 
indicate the percentage of either CD44-depleted or bulk CD8 cells. Axes 
on plots are displayed in Logicle scale. Numbers in the bottom row  
indicate the percentage of each population that is CD69+. Results  
represent n = 4 mice per tumor location in 2 independent experiments.
Figure 4.  Endogenous lymphocytes are not required for naive  
T cell infiltration into tumors or their in situ activation. C57BL/6 
mice or RAG2/ mice bearing s.c. tumors received Thy1-mismatched OT-I 
T cells. 24 h later, lymphocytes from tumors, LN, and spleen were har-
vested and stained for flow cytometry. Plots are gated on Thy1.1+ CD8+ 
lymphocytes, and numbers indicate the percentage of OT-I cells that are 
single positive for CD69 or CD25, or positive for both markers. Axes on 
plots are displayed in Logicle scale. Results represent two independent 
experiments with three mice each per group.JEM VOL. 207, August 2, 2010 
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Naive T cells that infiltrate tumors proliferate in situ
Because the tumor microenvironment is generally considered 
to be immunosuppressive, we next determined the fate of   
T cells activated there. 4 d after transfer, we observed divided 
OT-I cells in the tumor (Fig. 6 A). To eliminate the draining 
LN as a potential source of these divided TIL, we first used 
the sphingosine 1-phosphate analogue FTY720, which prevents 
T cell egress from LNs (Brinkmann et al., 2002; Brinkmann 
and Lynch, 2002). As observed previously (Sheasley-O’Neill 
et al., 2007), FTY720 treatment blocked the redistribution of 
divided OT-I cells from the draining LN to nondraining LN, 
which is normally seen by 4 d (Fig. 6 A and Fig. S4, A–C). 
However, significant numbers of divided tumor-specific T cells 
were still present in FTY720-treated animals bearing lung, s.c., 
or i.p. B16-cOVA, LLC-OVA, and B16-AAD tumors (Fig. 6, 
A and C, and not depicted). In the case of lung tumors, the 
spleen is also an initial priming site (Fig. 1 A). As it is contro-
versial whether FTY720 causes retention of T cells in the 
spleen, splenectomized mice were used as lung tumor recipi-
ents (Fig. 6 A). The decrease in representation of divided 
OT-I cells in nondraining LN relative to untreated controls 
was significantly larger than the corresponding decrease in 
the tumor (Fig. S4, A–C), suggesting that the divided OT-I 
cells present in the tumor did not arise from the draining LN. 
We confirmed this using mice lacking LNs. Divided OT-I 
cells were found 4 d after transfer into mice bearing estab-
lished s.c. or lung B16-cOVA tumors whose LNs had been 
ablated in utero (Fig. 6 C). Furthermore, the size of the   
tumor-infiltrating OT-I population in these LN-free mice was 
the same as the population in FTY720-treated animals with 
LNs in the same experiment. The lack of difference between 
these two populations further supports the conclusion that 
naive OT-I cells proliferate within tumors after being initially 
activated there. These results demonstrate that tumor masses, 
without any contribution from a draining LN, support the 
initial activation and proliferation of CD8 T cells.
FTY720 treatment reduced the size of the B16 melanoma-
infiltrating T cell population originating from the adop-
tively transferred OT-I cells, although it had no impact on 
endogenous T cells that had already infiltrated the tumor 
before treatment. However, although intratumorally primed 
T cells were always evident in tumors of FTY720-treated 
and LN-ablated mice, the size of this population depended 
on both tumor type and location. i.p. and s.c. tumors of 
FTY720-treated  animals  contained  the  smallest  popula-
tions relative to the corresponding tumors in untreated   
animals (15 ± 2% [n = 9] and 10 ± 2% [n = 11], respectively; 
Fig.  6,  A  and  B).  However,  the  intratumorally  primed 
population was a much larger fraction of the total TIL in 
lung tumors (40% ± 12%; n = 10). Interestingly, although 
the size of the TIL population in untreated mice bearing 
LLC-OVA tumors was much smaller than for B16, there 
was no diminution in the size of this population in FTY720-
treated animals (Fig. 6 C). This identifies intratumorally 
primed T cells as the most significant source of TIL in that 
tumor type.
Naive T cell infiltration and activation occurs in different 
tumor types and with T cells of different avidities
To determine whether tumors other than B16 could support 
naive T cell infiltration and activation, we used the Lewis lung 
carcinoma (LLC) transfected with OVA (LLC-OVA). 24 h after 
naive cell transfer, activated OT-I cells were present in established 
LLC-OVA tumors growing in different anatomical locations 
(Fig. 5 A). We also evaluated lower avidity FH TCR transgenic   
T cells, which recognize the endogenous tyrosinase-derived epi-
tope Tyr369 presented on B16-F1 melanoma cells transfected 
with the recombinant class I MHC molecule,  AAD (B16-AAD). 
Again, activated FH T cells were also present 24 h after naive cell 
transfer into AAD+ albino nice bearing established B16-AAD 
tumors (Fig. 5 B). In combination, these results indicate that in-
filtration of naive T cells into tumors and their subsequent activa-
tion is generalizable to different tumor types and T cell avidities.
Figure 5.  Naive T cell infiltration and activation within tumors 
extends to different tumor types and T cell avidities. C57BL/6 mice 
bearing established s.c. or i.p. LLC-OVA tumors (A) or AAD+ mice bearing 
established s.c., lung, or i.p. B16-AAD tumors (B) received Thy1-mis-
matched OT-I or FH T cells, respectively. 24 h later, tumors, LN, and spleen 
were harvested and stained for flow cytometry. Plots are gated on Thy1.1+ 
CD8+ OT-I cells (A) or Thy1.2+ CD8+ FH cells (B). Tumor location is indi-
cated to the right of dot plots. Numbers indicate the percentage of OT-I 
or FH cells that are single positive for CD69 or CD25, or positive for both 
markers. Axes on plots are displayed in Logicle scale. Results represent at 
least two independent experiments with three or more mice each for each 
tumor type and location.1796 Activation of naive T cells in tumor masses | Thompson et al.
Activation of naive intratumoral T calls occurs at multiple  
T cell precursor frequencies
Because the aforementioned experiments were done using 106 
adoptively transferred cells, it was of interest to know whether 
the T cells activated within the tumor represented a significant 
source of TIL at more physiological precursor frequencies. We 
titrated the OT-I adoptive transfer number from 104 to 106 in 
FTY720-treated, s.c., and i.p. B16-cOVA tumor-bearing   
animals. We observed divided T cells in the tumors of these 
animals at all precursor frequencies (Fig. 7). Although their 
representation among total lymphocytes decreased with de-
creasing transfer number, it was higher than expected given the 
differences in the number of transferred cells. This could be the 
result of more efficient infiltration of naive T cells into tumors 
or  of  more  efficient  expansion  of  intratumorally  activated   
T  cells  at  low  adoptive  transfer  number.  Regardless,  these   
results  suggest  that  activation  of  naive  intratumoral  T  cells 
could contribute to TIL in an endogenous situation.
CD8 T cells activated within tumors acquire  
effector function
We  next  asked  whether  activation  of  naive  CD8  T  cells 
within tumors generates functional effectors. When OT-I cells 
isolated 4 d after transfer from B16-cOVA tumors of FTY720-
treated mice were stimulated ex vivo with OVA257 peptide-
pulsed stimulators, a significant fraction secreted IFN- and 
most also expressed CD107a, a proxy for cytotoxic activity 
(Fig. 8 A). These effector functions were also acquired by T cells 
activated  in  different  tumor  types,  by  different  tumor   
antigens, and in different anatomical locations. The vast   
majority of intratumorally activated T cells also expressed 
Figure 6.  Naive T cells that infiltrate 
tumors proliferate in situ. (A and B) C57BL/6, 
ATA, or splenectomized C57BL/6 mice  
bearing established B16-cOVA, B16-AAD, or 
LLC-OVA tumors in the locations indicated 
received CFSE-labeled Thy1-mismatched OT-I 
or FH cells. FTY720 treatment was initiated at 
the time of T cell transfer and continued for 
the duration of the experiment. 4 d after T cell 
transfer, tumors and lymphoid organs were 
harvested, and lymphocytes were stained for 
flow cytometry. Only tumors are shown in B. 
Dot plots are gated on total lymphocytes. 
Numbers on dot plots indicate the percentage 
of tumor-specific T cells out of total lympho-
cytes. Axes on plots are displayed in Logicle 
scale. Histograms are gated on CD8+ OT-I or 
FH cells. Gates indicate all cells that have 
undergone at least one division. Results rep-
resent at least two independent experiments 
per tumor type, with at least three mice each. 
(C) Normal C57BL/6 mice or C56BL/6 mice 
lacking LN after in utero ablation were splenectomized. s.c. or lung tumors were established, and the mice received CFSE-labeled Thy 1.1+ OT-I cells. 
FTY720 treatment was initiated at the time of T cell transfer, and continued for the duration of the experiment. 4 d after T cell transfer, tumors were har-
vested and stained for flow cytometry. Plots are gated on total lymphocytes. Numbers on dot plots indicate the percentage of tumor-specific T cells out 
of total lymphocytes. Axes on plots are displayed in Logicle scale. Results represent n = 4 animals per tumor location in 2 independent experiments.
Figure 7.  Activation of naive intratumoral T calls occurs at mul-
tiple T cell precursor frequencies. C57BL/6 bearing established s.c. or i.p. 
B16-cOVA tumors received 104, 105, or 106 CFSE-labeled Thy1-mis-
matched OT-I cells. FTY720 treatment was initiated at the time of T cell 
transfer and continued for the duration of the experiment. 5 d after T cell 
transfer, tumors and lymphoid organs were harvested and lymphocytes 
were stained for flow cytometry. Tumor location is indicated to the right 
of dot plots. Dot plots in A are gated on total lymphocytes. Numbers in 
dot plots indicate the percentage of OT-I cells out of total lymphocytes in 
the tumor. Axes on plots are displayed in Logicle scale. Results represent  
2 independent experiments, with n = 3–4 mice each for each tumor  
location and are summarized in B.JEM VOL. 207, August 2, 2010 
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Sheasley-O’Neill et al., 2007) or vaccinia virus expressing OVA 
(40–70% IFN-+, 70% Granzyme B+ OT-I cells; Fig. S6).
A potential concern with the aforementioned experiment 
is that CD8 T cells could be suppressed in vivo, but might 
recover rapidly during an ex vivo stimulation. Therefore, we 
administered  Brefeldin  A  (BFA)  to  FTY720-treated  B16-
cOVA-bearing mice to cause the accumulation of any IFN- 
produced by OT-I cells while they still remain exposed to 
both antigen and potential suppressive factors in the tumor. 
When OT-I cells were isolated and analyzed 4 h after BFA 
treatment without additional ex vivo stimulation, one third 
to one half of the cells had accumulated IFN- (Fig. 8 C). 
Again there was an evident increase in the fraction of func-
tional effectors and their absolute number between 4 and 8 d 
of  tumor  residence.  Importantly,  intratumorally  activated   
T cells were able to kill peptide-pulsed target cells in vitro, 
Granzyme B (Fig. 8 D). Although a slightly lower percentage 
of OT-I cells in the tumor were Granzyme B+ as compared 
with cells in the draining LN of the same animal, this is   
consistent with extensive degranulation of these tumor- 
infiltrating cells in vivo as they continually encounter tumor 
cells. When T cells were isolated 8 d after transfer, an even 
higher overall percentage of OT-I cells expressed these effec-
tor functions, and the representation of dual functional (IFN-+ 
and CD107a+) effectors more than doubled (Fig. 8 B).   
The percentage of intratumorally activated T cells expressing 
effector functions was equivalent to or greater than that of   
T cells activated in the draining LN of the same animal (Fig. S5, 
A–C). The expression of effector function by intratumorally 
activated  T  cells  was  also  comparable  to  that  of  T  cells   
activated by peptide-pulsed, CD40L-activated BM-derived 
DCs (20–45% IFN-+ OT-I cells; Hargadon et al., 2006; 
Figure 8.  CD8 T cells activated within tumors 
acquire effector function. (A and B) Ex vivo analysis 
of tumor-specific T cell function. Mice bearing estab-
lished B16-cOVA, B16-AAD, or LLC-OVA in the  
indicated locations received CFSE-labeled  
Thy1-mismatched OT-I or FH cells. FTY720 treatment 
was initiated at the time of T cell transfer and contin-
ued for the duration of the experiment. 4 (A) or 8 (B) d 
after T cell transfer, tumors were harvested and 
stained for flow cytometry after a brief ex vivo  
restimulation. Plots are gated on tumor-specific 
Thy1.1+ CD8+ OT-I cells. Numbers on plots indicate the 
total percentage of OT-I cells that are single positive 
for IFN- or CD107a or double positive for both mark-
ers. Axes on plots are displayed in Logicle scale. 
Graphs summarize the composition of the antitumor 
effector response (A) and compare the antitumor 
response at 4 and 8 d after T cell transfer (B). Results 
represent at least two independent experiments with 
at least three mice per tumor type. (C) Analysis of 
in vivo IFN- production by tumor-specific T cells. 
C57BL/6 mice bearing established i.p. B16-cOVA  
tumors were given CFSE-labeled OT-I cells. FTY720 
treatment was initiated at the time of T cell transfer 
and continued for the duration of the experiment 4 or 
8 d after T cell transfer, mice were treated with BFA, 
and 4 h later tumors were harvested and stained for 
flow cytometry. Dot plots are gated on Thy1.1+ CD8+ 
OT-I cells. Numbers on plots indicate the percentage 
of OT-I cells that are divided (CFSE negative) and  
IFN-+. Axes on plots are displayed in Logicle scale. 
Graph summarizes in vivo IFN- production and the 
number of OT-I cells in the tumor. Results represent 2 
independent experiments, with n = 3 mice at each 
time point. Statistical analyses in (A and B) were  
performed using a two-tailed Student’s T test (Prism version 5.0; GraphPad Software, Inc.). (D) Granzyme B expression. Lymphocytes were isolated from s.c. 
tumors and tumor-draining LN of FTY720-treated animals 4 d after initial naive cell transfer. Gray histogram indicates isotype control staining and black 
histogram indicates staining on OT-I T cells. Histograms are gated on Thy1.1+ CD8+ lymphocytes. Axes on plots are displayed in Logicle scale. Graph summa-
rizes the percentage of divided OT-I that express Granzyme B when activated in the tumor or the draining LN. Staining was performed with n = 6 mice in  
1 experiment. (E) In vitro cytotoxicity of intratumorally primed OT-I cells. Thy1.1+ OT-I cells were isolated from i.p. tumors and tumor-draining LN of FTY720-
treated animals 4 d after initial naive cell transfer, and then incubated with a mix of CFSE-labeled peptide-pulsed and unpulsed targets. Histograms are 
gated on CFSE-labeled target cells. Numbers on histograms represent the percentage of target cells that are CFSElo or CFSEhi. Axes on plots are displayed in 
Logicle scale. Results represent pooling of OT-I cells from eight tumors and eight tumor-draining LN in each of three independent experiments.1798 Activation of naive T cells in tumor masses | Thompson et al.
DISCUSSION
In this study, we investigated the capacity of tumors to support 
the entry and activation of naive CD8 T cells. Naive T cells 
were found in tumors lacking relevant antigen and significant 
numbers of activated T cells were found within 24 h in tumors 
that did express the relevant antigen. The presence of these acti-
vated T cells was independent of the presence of a draining LNs 
or endogenous B and T cells. These early infiltrating cells subse-
quently proliferated and acquired multiple markers of effector 
function. We observed similar processes of activation in different 
tumor types and with tumor-specific T cells of different avidi-
ties. Both cross-presenting APCs in the tumor and tumor cells 
themselves were capable of mediating naive T cell activation and 
differentiation. Our results show that naive T cells can infiltrate 
tumors regardless of the presence of antigen, and can become 
fully differentiated effectors when cognate antigen is present. 
Although the precise contribution of intratumorally activated   
T cells to overall antitumor immunity remains to be determined, 
indicating that the other markers of effector function we   
observed correlated with actual cytotoxic ability (Fig. 8 E). 
These results demonstrate that tumors can support the activa-
tion, expansion, and in vivo effector activity of initially naive 
intratumoral CD8 T cells. In addition, they show that intra-
tumorally activated effectors retain their functionality in vivo, 
despite prolonged exposure to potentially suppressive factors 
in the tumor microenvironment.
Both tumor cells and cross-presenting APCs induce  
the activation, proliferation, and effector differentiation  
of naive intratumoral CD8 T cells
We  sought  to  determine  which  cells  within  the  tumor 
mediated the activation of intratumoral CD8 T cells. To 
evaluate  the  importance  of  cross-presenting  APCs,  we 
eliminated  direct  antigen  presentation  by  tumor  cells. 
B16-F1 expresses tyrosinase but lacks the AAD MHC I 
molecule necessary to present the Tyr369 epitope. AAD+ 
mice  bearing  established  B16-F1  tumors  received   
Tyr369-specific FH T cells, and in long-term experiments,   
repeated  administration  of  FTY720.  Intratumoral  FH   
T cells up-regulated CD69 and CD25 24 h after transfer, 
proliferated, and acquired the ability to secret IFN- and 
degranulate 4 d later (Fig. 9, A–C). These results demon-
strate the presence of functional cross-presenting APCs in 
the tumor.
To determine whether direct presentation by the tumor 
could activate naive CD8 T cells, we eliminated cross- 
presentation of the OVA257 epitope using bm1→C57BL/6 
chimeras bearing B16-cOVA. The BM-derived compart-
ment of these mice is unable to present tumor antigen to 
OT-I T cells. OT-I activation and proliferation was dras-
tically reduced in the draining LN of tumor-bearing chi-
meras,  demonstrating  that  cross-presentation  had  been 
effectively eliminated. However, activation, proliferation, 
and acquisition of effector function by intratumoral OT-I 
cells in chimeras was comparable to that seen in normal 
C57BL/6 animals (Fig. 10, A, B, and D). To eliminate the 
possibility of continued cross-presentation by a radioresis-
tant cell in the tumors of these chimeras, 2M/ mice 
lacking  MHC  class  I  expression  were  challenged  with 
B16-cOVA. Activation of transferred naive OT-I cells re-
mained apparent in the tumors of these mice, although the 
percentage of CD69+ OT-I cells was somewhat decreased 
compared with that in tumors of bm1 chimeras. This is 
consistent with the possibility that a radioresistant cell may 
also cross-present antigen in the tumor. Although we can-
not rule out the possibility of “cross-dressing” of bm1 or 
2M/  mice  APCs  with  MHC–OVA257  peptide  com-
plexes derived from the tumor (Dolan et al., 2006), we 
consider that direct presentation by the tumor cells them-
selves  accounts  for  the  majority  of  OT-I  activation  in 
these animals. We conclude that APCs cross-presenting 
tumor antigen and tumor cells directly presenting antigen 
are each sufficient to direct the effector differentiation of 
naive intratumoral T cells.
Figure 9.  Intratumoral cross-presenting APCs are sufficient for 
the activation and effector differentiation of naive CD8 T cells.  
(A and B) ATA bearing established s.c., lung, or i.p. B16-F1 tumors received 
Thy1-mismatched unlabeled (A) or CFSE-labeled FH T cells. 24 h (A) or 4 d (B) 
after T cell transfer, tumors and lymphoid organs were harvested and 
stained for flow cytometry. In B, FTY720 treatment was initiated at the 
time of T cell transfer and continued for the duration of the experiment. 
All plots are gated on Thy1.2+ CD8+ FH lymphocytes. Numbers in A indi-
cate the percentage of FH cells are single positive for CD69 or CD25, or 
positive for both markers. Gates on plots in B indicate FH cells that have 
undergone at least one division. Axes on plots are displayed in Logicle 
scale. (C) Ex vivo effector analysis. FH cells from tumors harvested 4 d 
after T cell transfer were also briefly restimulated ex vivo and stained for 
IFN- and CD107a. The composition of the antitumor effector response in 
each tumor location is summarized in C. Results are represent n = 6 mice 
per tumor location and time point in 4 independent experiments, 2 with  
s.c. tumors and 1 each with i.p. and lung tumors.JEM VOL. 207, August 2, 2010 
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However,  multiple  studies  have  demonstrated  that  naive   
T cells infiltrate peripheral tissues as part of their normal mi-
gratory activity (Westermann et al., 1996; Zippelius et al., 2004; 
Cose et al., 2006, 2007; Galkina et al., 2006; Staton et al., 
2006). Robust naive T cell recruitment to inflamed periph-
eral tissues has also been reported in the setting of infection, 
autoimmune disease, and graft rejection (Kobayashi et al., 
2004; Drayton et al., 2006; Lee et al., 2006; Nasr et al., 2007). 
Naive T cells infiltrate tumors engineered to express LIGHT 
or lymphotoxin  (Schrama et al., 2001; Kim et al., 2004; Yu 
et al., 2004), or tumors injected with DCs genetically modified 
to express CCL21 (Kirk et al., 2001). Our work extends this 
body of literature and demonstrates that recruitment of naive 
T cells to tumors occurs in the absence of any artificially in-
troduced inflammatory stimulus or manipulation.
The infiltration of naive T cells into tumors may result from 
normal, stochastic migration of these cells through nonlymphoid 
sites or their specific attraction to an inflamed nonlymphoid site, 
a phenomenon that often correlates with the presence of tertiary 
lymphoid organs (TLOs; Drayton et al., 2003; Weninger et al., 
2003; Kobayashi et al., 2004; Drayton et al., 2006; Lee et al., 
2006). Some human tumors have been shown to contain lym-
phoid aggregates resembling TLO (Bell et al., 1999; Coronella 
et al., 2002; Miyagawa et al., 2004; Ladányi et al., 2007). A dif-
ferent B16 tumor than the one used in our study has also been 
reported to express CCL21, a chemokine which could attract 
naive T cells, and to develop a lymphoidlike stroma, whereas 
traditional TLO were not observed (Shields et al., 2010). It is an 
attractive possibility that the chronic inflammatory environment 
within tumors could drive the development of TLO that might 
promote the recruitment of naive CD8 T cells to the tumor. 
Development of TLO has been shown to be independent of 
lymphoid tissue-inducer cells, but dependent on the presence of 
CD4 T cells and DCs (Marinkovic et al., 2006; GeurtsvanKessel 
et al., 2009; Halle et al., 2009). Our observation of continued 
naive T cell infiltration of tumors and in situ activation in 
RAG/ animals suggests that TLO are not absolutely required 
for these processes. Multiple pathways may exist for the infiltra-
tion of naive T cells into tumors, and TLO could represent one 
of these. Although not required, TLO and endogenous lym-
phocytes might enhance naive T cell infiltration and could qual-
itatively alter the tumor microenvironment by producing 
chemokines and other inflammatory mediators that could sup-
port activation of naive T cells. Further work is needed to un-
derstand the requirements for naive T cell infiltration into tumors 
and whether tumor vasculature resembles that of normal tissue, 
or recapitulates the vasculature and microenvironment of an   
inflamed tissue.
Our finding that intratumoral APCs cross-presenting   
tumor antigen can activate naive T cells is consistent with pre-
vious studies demonstrating similar functionality for APCs 
resident in tumor-draining LNs (Nelson et al., 2001; Spiotto 
et al., 2002; Hargadon et al., 2006). However, the observa-
tion that tumor cells directly drive naive T cell activation and 
effector differentiation is unexpected. Most tumors do not 
express the co-stimulatory molecules CD80 and CD86 and 
our results clearly demonstrate that these cells possess the poten-
tial for antitumor activity while residing in the immunosuppres-
sive tumor microenvironment.
The observation that both tumor-specific and nonspecific 
naive T cells can infiltrate multiple tumor types runs counter 
to the widely held view that naive T cells cannot access pe-
ripheral tissues. Naive T cell trafficking is highly skewed   
toward lymphoid organs (von Andrian and Mackay, 2000). 
Figure 10.  Tumor cells directly presenting antigen are sufficient 
for the activation and effector differentiation of naive CD8 T cells. 
Bm1 → B6 BM chimeras (A and B) bearing established s.c., lung, or i.p. 
B16-cOVA tumors or 2M/ mice bearing established s.c. or i.p. tumors (C) 
received Thy1-mismatched unlabeled (A and C) or CFSE-labeled (B) OT-I 
T cells. 24 h (A and C) or 4 d (B) after T cell transfer, tumors and lymphoid 
organs were harvested and lymphocytes were stained for flow cytometry. 
Graph in C summarizes the initial activation of OT-I cells in control mice, 
bm1 chimeras, and 2M/ mice In (B) FTY720 treatment was initiated at 
the time of T cell transfer and continued for the duration of the experi-
ment. All plots are gated on Thy1.1+ CD8+ OT-I lymphocytes. Numbers in 
(A and C) indicate the percentage of OT-I cells that are single positive for 
CD69 or CD25, or positive for both markers. Gates on plots in (B) indicate 
OT-I cells that have undergone at least one division. Axes on plots are 
displayed in Logicle scale. (D) Ex vivo effector analysis. OT-I cells from 
tumors harvested 4 d after T cell transfer were also briefly restimulated 
ex vivo and stained for IFN- and CD107a. The composition of the anti-
tumor effector response in each tumor location is summarized in (C).  
Results (A, B, and D) represent n = 6 mice per tumor location and time 
point in 4 independent experiments, 2 with s.c. tumors and 1 each with  
i.p. and lung tumors. Results in C represent 3 s.c. and 3 i.p. tumor-bearing 
animals in 2 independent experiments.1800 Activation of naive T cells in tumor masses | Thompson et al.
Beyond the initial activation and proliferation of T cells 
within tumors, our work also demonstrates high levels of in 
vivo functionality among intratumorally primed CD8 T cells. 
Other groups have also described functional TIL within both 
B16 and LLC masses (Prévost-Blondel et al., 1998; Nelson   
et al., 2001), but the tumors inevitably grow out in their hosts 
despite the presence of these functional tumor-specific CD8 
effectors. Thus, although functional T cells can be observed 
within  tumors,  they  are  typically  unable  to  control  tumor 
growth. Several factors could contribute to this lack of control: 
an insufficient number of functional T cells might be present, 
T cells might become exhausted in the face of high levels of 
chronic antigen (Shin and Wherry, 2007; Mueller and Ahmed, 
2009), or T cells might be actively suppressed within the tumor 
microenvironment (Zou, 2005; Rabinovich et al., 2007). Sev-
eral  immunosuppressive  mechanisms  including  T  reg  cells 
(Ghiringhelli et al., 2005), STAT-3 activation (Wang et al., 
2004; Kortylewski et al., 2005), myeloid-derived suppressor 
cell (Gabrilovich et al., 2001; Sica and Bronte, 2007), and IDO 
(Friberg et al., 2002; Munn et al., 2004) have been described 
for either B16 or LLC. B16 has also been suggested to foster a 
tolerogenic environment via a CCL21-driven development of 
lymphoidlike stroma (Shields et al., 2010). Although CCL21 
could therefore both recruit naive T cells and support their 
suppression, a direct impact on newly tumor-infiltrating naive 
T cells was not evaluated. Immunosuppression could limit the 
infiltration of naive T cells into tumors, the number of func-
tional cells that can be generated (Kortylewski et al., 2005; 
Fridlender et al., 2009), or could curtail T cell function over 
time. However, our work clearly demonstrates that immuno-
suppression within B16 and LLC tumors is not sufficient to 
prevent the initial activation and differentiation of naive CD8 
T cells nor to eliminate their in vivo functionality. The finding 
that tumors support naive T cell differentiation suggests that 
the tumor itself could be exploited therapeutically as a vaccina-
tion site (Jackaman et al., 2008) for the in situ development of 
functional T cells. In situ activation of T cells in the tumor 
could address several potential culprits for the failure of the anti-
tumor response. Our results show that the fraction of naive   
T cells that are activated in the tumor is much larger than that 
in the draining LN, likely caused by the large depot of antigen 
available in the tumor mass. Although the efficiency of naive   
T cell infiltration into tumors clearly limits the contribution of 
intratumorally cells to the total TIL population, intratumoral 
injection  of  chemoattractants  (Kirk  et  al.,  2001;  Furumoto   
et al., 2004; Wong et al., 2008) or naive T cells themselves 
could overcome this limitation. This also provides the poten-
tial for repetitive injection, leading to a constant source of 
functional cells as long as antigen remains available.
In conclusion, this study demonstrates that tumors sup-
port the infiltration, activation, and effector differentiation of 
naive T cells. These T cells express this function in the tumor 
for prolonged periods of time. Although endogenous T cell 
responses often fail to control tumors, our results identify a 
therapeutic opportunity to harness intratumoral antigen pre-
sentation to enhance antitumor immunity in situ.
would be considered nonprofessional APCs. The differences 
in the percentage of naive OT-I cells that became activated 
in bm1 chimeras versus 2M/ mice suggested that a radio-
resistant cell within tumors may also cross-present antigen. 
However, as our chimeras successfully eliminate >95% of 
professional APCs, this cell is likely to also be a nonprofes-
sional APC, and the same set of questions regarding the abil-
ity of this cell type to activate naive T cells is relevant. TCR 
stimulation alone is usually insufficient for induction of a pro-
ductive T cell response (Shahinian et al., 1993; Acuto and 
Michel, 2003; Smith-Garvin et al., 2009). However, responses 
to skin allografts (Kawai et al., 1996) and viruses with high 
replicative potential (Shahinian et al., 1993) can proceed in 
mice deficient in CD28, suggesting that high TCR occu-
pancy can provide the signal amplification normally provided 
through CD28 co-stimulation (Acuto and Michel, 2003). In-
creased duration of TCR signaling can also overcome the 
necessity of CD28 co-stimulation (Kündig et al., 1996). The 
large number of tumor cells present in an established tumor 
may also provide a continuous, high level of antigen that by-
passes CD28 signaling. Alternatively, tumor cells might express 
another molecule that serves a co-stimulatory function. Both 
CD24 and CD70 are expressed by certain tumors and have 
been shown to provide co-stimulation for naive T cells 
(Wang et al., 1995; Watts, 2005; Boursalian et al., 2009). 
CD24 is expressed by B16, the melanoma used in our study 
(Niers et al., 2009). In addition, a wide range of human and 
mouse tumors, including B16 (Morimoto et al., 2008), express 
ligands for DNAM-1, which has been shown to aid T cell 
recognition of antigen displayed by nonprofessional APCs 
(Gilfillan et al., 2008). Thus, the combination of high levels of 
antigen and potential expression of other molecules with co-
stimulatory function may compensate for the lack of classical 
co-stimulatory molecules when tumor cells or other nonpro-
fessional APCs are the source of antigen for naive T cells.
The extranodal activation of T cells within tumors identi-
fies a previously unappreciated source of TIL. Although it is 
difficult to estimate the proportion of TIL that may arise from 
activation within the draining LN versus the tumor itself, in-
tratumorally activated T cells clearly do contribute to the 
overall CD8 T cell response present in tumors. Interestingly, 
the contribution of the LN and the tumor as sources of TIL 
varies by tumor type and location. Although the LN draining 
B16 tumors contributes most of the TIL in those tumors, 
lung B16 in particular can generate a substantial percentage of 
the total population. In contrast, the representation of tumor-
specific T cells in LLC tumors after FTY720 treatment is 
equal to or greater than that seen in untreated tumor-bearing 
animals. This suggests that LLC tumors produce a larger frac-
tion of their own TIL than their draining LNs. These differ-
ences between tumors could reflect variation at several points: 
efficiency of priming in the draining LN, migration of cells 
from the draining LN to the tumor, initial infiltration of 
naive T cells into different tumors, or the ability of tumors in 
different locations to support the proliferation or survival of 
intratumorally primed T cells.JEM VOL. 207, August 2, 2010 
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(Roche) and 60 U/ml DNase I (Sigma-Aldrich) for 30 min at 37°C. When 
possible, large tumor nodules were dissected away from normal tissue. All 
tissues and tumors were then homogenized, filtered through nylon mesh, 
and lymphocytes were isolated on Lympholyte-M (Cedarlane). When BM 
was taken, cells were harvested by repeatedly flushing the femurs and tibias 
from each mouse with PBS.
Flow cytometry. Single-cell suspensions from LN or spleen and lympho-
cytes isolated from lungs, liver, or tumors were incubated with CD16/32 
(2.4G2; BioXCell) to block Fc receptors, and then with one or more of the 
following: APC-Alexa Fluor 750 anti-CD8 (53–6.7), PerCP-Cy5.5 anti-
Thy1.1 (HIS51), FITC anti-CD69 (H1.2F3), PE anti-CD25 (PC61.5), PE 
anti-CD44 (IM7), PE anti-CD107a (1D4B), APC anti-IFN- (XMG1.2), 
APC-Alexa  Fluor  750  anti-CD45.1  (A20),  PerCP-Cy5.5  anti-CD45. 
2 (104), FITC anti-CD11c (N418), PE anti-CD11b (M1/70), and APC 
anti-Ly-6G,C (Gr-1; all from eBioscience); APC-Cy7 anti CD4 (GK1.5; 
BD); and PerCP anti-Thy1.2 (30-H12; BioLegend). Samples were run on a 
FACSCanto (BD) and analyzed using FlowJo software (Tree Star, Inc.).
Immunofluorescence microscopy. LNs, s.c. tumors, and tumor-bearing 
lung lobes were flash frozen in liquid nitrogen and subsequently cut into   
6-µM slices in the Research Histology Core at the University of Virginia 
School of Medicine. Tissue sections were fixed with acetone and incubated 
with CD16/32 (2.4G2; BioXCell) to block Fc receptors. Sections were 
blocked with a Biotin-Avidin Blocking kit (Vector Laboratories) and stained 
with FITC anti-CD31(390) and biotinylated anti-Thy1.1(HIS51); followed 
by DyLight-488 anti-FITC (Jackson ImmunoResearch Laboratories) and 
Texas red streptavidin (SouthernBiotech). Slides were mounted in Vecta-
shield with DAPI (Vector Laboratories). Sample slices were counterstained 
with hematoxylin and eosin by the Research Histology Core (University of 
Virginia School of Medicine) to examine LN and tumor structure; this was 
done in combination with DAPI, which was used to distinguish normal lung 
tissue from tumor nodules.
Ex vivo analysis of tumor-specific T cell function. OT-I and FH cells 
isolated from tissues and tumors were incubated with LB15.13 cells pulsed 
with 10 µM OVA257 or AAD-transfected C1R lymphoblastoid cells pulsed 
with 10 µM Tyr369, respectively, for 5 h at 37°C. Media was supplemented 
with 50 U/ml IL-2 (Chiron), 10 µg/ml monensin (BD), and 10 µg/ml 
brefeldin-A (Sigma-Aldrich). CD16/32 was used to block Fc receptors for 
15 min before PE anti-CD107a antibody was added for the duration of the 
5-h stimulation. Cells were then stained for surface molecule expression, 
fixed,  and  permeabilized  using  Cytofix/Cytoperm  (BD)  and  stained  for   
intracellular IFN-.
In  vivo  analysis  of  tumor-specific  T  cell  production  of  IFN-.  
Tumor-bearing mice were injected i.p. with 250 ng of Brefeldin-A (Sigma-
Aldrich). 4 h later, TILs were immediately isolated and stained for surface 
molecule expression, and then fixed, permeabilized, and stained for intracel-
lular IFN-.
Ex vivo analysis of tumor-specific T cell cytotoxicity. Lymphocytes 
isolated from tumors were incubated with anti-Thy1.1 microbeads (Miltenyi 
Biotec). Thy1.1+ OT-I cells were positively selected using an AutoMACS 
Pro Separator (Miltenyi Biotec). OT-I cells were then co-cultured for 5 h at 
37°C at fixed ratios with a 1:1 mix of LB15.13 cells pulsed with 10 µM 
OVA257 and stained with 1 µM CFSE and unpulsed LB15.13 cells stained 
with 0.1 µM CFSE. Media was supplemented with 50 U/ml IL-2 (Chiron). 
Percent killing was assessed by evaluating percent loss of the peptide-pulsed 
population relative to the unpulsed population.
Online  supplemental  material.  Fig.  S1  shows  gating  of  transferred   
tumor-specific T cells and CD69 and CD25 expression on endogenous TIL. 
Fig. S2 shows that naive T cells become activated within lung tumors in 
mice lacking a tumor DLN. Fig. S3 shows enrichment of 4 and CD11a 
MATERIALS AND METHODS
Mice. C57BL/6 and CD45.1 congenic (NCI-Frederick Animal Production 
Program), OT-I RAG1/, and RAG2/ mice (Taconic), Thy1.1 con-
genic, bm1, and 2M/ mice (Jackson Immunoresearch Laboratories) were 
maintained under specific pathogen–free conditions. C57BL/6 albino mice 
with a deletion of the tyrosinase locus and expressing AAD, a MHC class I 
molecule composed of the 1 and 2 domains of HLA-A*0201, and the   
3 domain of the H2-Dd have been previously described (Colella et al., 2000). 
FH TCR transgenic mice expressing a TCR-specific for the Tyr369 epitope 
in the context of AAD and have been previously described (Nichols et al., 
2007). Protocols were approved by the University of Virginia Institutional 
Animal Care and Use Committee.
In utero ablation of LN. Pregnant C57BL/6 females were injected i.v. on 
gestational d 8, 11, and 14 with 100 µg of lymphotoxin- receptor-Ig and 
TNF receptor 55-Ig fusions proteins in 200 µl sterile saline as previously de-
scribed (Rennert et al., 1998). Absence of LN was confirmed by extensive 
dissection at the time of necropsy. Protocol was adapted from previously de-
scribed methods.
Splenectomy. 8-wk-old C57BL/6 or Thy-1.1+ AAD+ albino mice were 
splenectomized and allowed to recover for at least 2–3 wk before tumor 
challenge or other manipulation.
BM chimeras. C57BL/6 CD45.1 congenic mice were lethally irradiated 
(650 rad × 2) and reconstituted with 4 × 106 bm1 BM cells that had been 
depleted of CD4+ and CD8+ cells (Miltenyi Biotec). Chimerism of all mice 
was confirmed 8 wk after irradiation by sampling peripheral blood via the 
lateral tail vein. On average, >95% of all CD45+ cells and of all cell subsets 
with high potential for antigen presentation (CD11c, CD11b, and Gr-1) 
were of donor origin (CD45.2+).
Tumor cells and injections. B16-F1 mouse melanoma cells were ob-
tained  from  American  Type  Culture  Collection.  B16-cOVA  (Hargadon   
et al., 2006) and B16-AAD (Mullins et al., 2001) have been previously de-
scribed. LLC transfected to express cOVA was a gift of E. Podack (University 
of Miami, Miami, FL). 4 × 105 tumor cells were injected i.v. via the lateral 
tail vein, s.c. in the nape of the neck, or i.p. to establish tumors in the lungs, 
subcutaneous space, or i.p. cavity, respectively. Tumors in the peritoneum 
grow as a solid mass. Tumors were allowed to establish in the animal (10–15 d 
 for i.p.; 17–21 d for i.v. or s.c.), before any other manipulations, unless   
otherwise noted.
Adoptive transfer of TCR transgenic T cells. In experiments evaluat-
ing infiltration and activation at 24 h, 4 × 106 T cells from spleen and pooled 
LN of OT-I Thy1.1 or FH TCR transgenic mice were injected. Except 
where indicated, in experiments evaluating division and effector function   
4 or 8 d after transfer, 106 cells were injected that had been labeled before 
injection with 5 µM CFSE for 15 min at 37°C.
CD44+ cell depletion. Single-cell suspensions from pooled LN and spleen 
of OT-I Thy1.1 mice were enriched for CD8 T cells using a negative selec-
tion kit (Miltenyi Biotec). Enriched CD8 T cells were then incubated with 
PE-labeled anti-CD44 antibody and anti-PE microbeads (Miltenyi Biotec) 
to remove CD44+ CD8 T cells from the bulk CD8 population.
FTY720 treatment. Mice were injected i.p. at the time of T cell transfer 
with 1 mg/kg FTY720 (gift from V. Brinkmann, Novartis Pharma AG, Basel, 
Switzerland) in sterile saline and maintained on drinking water containing   
2 µg/ml FTY720 for the duration of the experiment.
Processing of tissues and tumors. To isolate lymphocytes from the lungs 
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